Listing 1 - 10 of 15 | << page >> |
Sort by
|
Choose an application
Biopharmaceutical and pharmaceutical manufacturing are strongly influenced by the process analytical technology initiative (PAT) and quality by design (QbD) methodologies, which are designed to enhance the understanding of more integrated processes. The major aim of this effort can be summarized as developing a mechanistic understanding of a wide range of process steps, including the development of technologies to perform online measurements and real-time control and optimization. Furthermore, minimization of the number of empirical experiments and the model-assisted exploration of the process design space are targeted. Even if tremendous progress has been achieved so far, there is still work to be carried out in order to realize the full potential of the process systems engineering toolbox. Within this reprint, an overview of cutting-edge developments of process systems engineering for biopharmaceutical and pharmaceutical manufacturing processes is given, including model-based process design, Digital Twins, computer-aided process understanding, process development and optimization, and monitoring and control of bioprocesses. The biopharmaceutical processes addressed focus on the manufacturing of biopharmaceuticals, mainly by Chinese hamster ovary (CHO) cells, as well as adeno-associated virus production and generation of cell spheroids for cell therapies.
Technology: general issues --- History of engineering & technology --- clonal cell population --- phenotypic diversity --- inoculum train --- uncertainty-based --- cell culture model --- biopharmaceutical manufacturing --- Escherichia coli --- hybrid modeling --- machine learning --- model-assisted DoE --- quality by design --- upstream bioprocessing --- surface plasmon resonance (SPR) --- bioprocess --- monitoring --- biosensor --- quality by design (QbD) --- process analytical technology (PAT) --- biotherapeutics production --- vaccines production --- CHO DP-12 --- computational fluid dynamics --- bioreactor characterization --- hydrodynamic gradients --- process development --- critical shear stress --- Kolmogorov length scale --- operational space --- sensors --- cell culture --- spectroscopy --- PAT --- smart biomanufacturing --- soft-sensor --- Adeno-associated virus --- transfection --- PEI --- continuous --- gene therapy --- microcarriers --- bioreactor --- transient expression --- spheroid strength --- β-cells --- diabetes --- shear stress-guided production --- hydrodynamic stress --- Gaussian processes --- Bayes optimization --- Pareto optimization --- multi-objective --- seed train --- Chinese hamster ovary cells --- cryopreservation --- monoclonal antibodies --- N−1 perfusion --- process intensification --- upstream processing --- clonal cell population --- phenotypic diversity --- inoculum train --- uncertainty-based --- cell culture model --- biopharmaceutical manufacturing --- Escherichia coli --- hybrid modeling --- machine learning --- model-assisted DoE --- quality by design --- upstream bioprocessing --- surface plasmon resonance (SPR) --- bioprocess --- monitoring --- biosensor --- quality by design (QbD) --- process analytical technology (PAT) --- biotherapeutics production --- vaccines production --- CHO DP-12 --- computational fluid dynamics --- bioreactor characterization --- hydrodynamic gradients --- process development --- critical shear stress --- Kolmogorov length scale --- operational space --- sensors --- cell culture --- spectroscopy --- PAT --- smart biomanufacturing --- soft-sensor --- Adeno-associated virus --- transfection --- PEI --- continuous --- gene therapy --- microcarriers --- bioreactor --- transient expression --- spheroid strength --- β-cells --- diabetes --- shear stress-guided production --- hydrodynamic stress --- Gaussian processes --- Bayes optimization --- Pareto optimization --- multi-objective --- seed train --- Chinese hamster ovary cells --- cryopreservation --- monoclonal antibodies --- N−1 perfusion --- process intensification --- upstream processing
Choose an application
Biopharmaceutical and pharmaceutical manufacturing are strongly influenced by the process analytical technology initiative (PAT) and quality by design (QbD) methodologies, which are designed to enhance the understanding of more integrated processes. The major aim of this effort can be summarized as developing a mechanistic understanding of a wide range of process steps, including the development of technologies to perform online measurements and real-time control and optimization. Furthermore, minimization of the number of empirical experiments and the model-assisted exploration of the process design space are targeted. Even if tremendous progress has been achieved so far, there is still work to be carried out in order to realize the full potential of the process systems engineering toolbox. Within this reprint, an overview of cutting-edge developments of process systems engineering for biopharmaceutical and pharmaceutical manufacturing processes is given, including model-based process design, Digital Twins, computer-aided process understanding, process development and optimization, and monitoring and control of bioprocesses. The biopharmaceutical processes addressed focus on the manufacturing of biopharmaceuticals, mainly by Chinese hamster ovary (CHO) cells, as well as adeno-associated virus production and generation of cell spheroids for cell therapies.
Technology: general issues --- History of engineering & technology --- clonal cell population --- phenotypic diversity --- inoculum train --- uncertainty-based --- cell culture model --- biopharmaceutical manufacturing --- Escherichia coli --- hybrid modeling --- machine learning --- model-assisted DoE --- quality by design --- upstream bioprocessing --- surface plasmon resonance (SPR) --- bioprocess --- monitoring --- biosensor --- quality by design (QbD) --- process analytical technology (PAT) --- biotherapeutics production --- vaccines production --- CHO DP-12 --- computational fluid dynamics --- bioreactor characterization --- hydrodynamic gradients --- process development --- critical shear stress --- Kolmogorov length scale --- operational space --- sensors --- cell culture --- spectroscopy --- PAT --- smart biomanufacturing --- soft-sensor --- Adeno-associated virus --- transfection --- PEI --- continuous --- gene therapy --- microcarriers --- bioreactor --- transient expression --- spheroid strength --- β-cells --- diabetes --- shear stress-guided production --- hydrodynamic stress --- Gaussian processes --- Bayes optimization --- Pareto optimization --- multi-objective --- seed train --- Chinese hamster ovary cells --- cryopreservation --- monoclonal antibodies --- N−1 perfusion --- process intensification --- upstream processing --- n/a
Choose an application
Biopharmaceutical and pharmaceutical manufacturing are strongly influenced by the process analytical technology initiative (PAT) and quality by design (QbD) methodologies, which are designed to enhance the understanding of more integrated processes. The major aim of this effort can be summarized as developing a mechanistic understanding of a wide range of process steps, including the development of technologies to perform online measurements and real-time control and optimization. Furthermore, minimization of the number of empirical experiments and the model-assisted exploration of the process design space are targeted. Even if tremendous progress has been achieved so far, there is still work to be carried out in order to realize the full potential of the process systems engineering toolbox. Within this reprint, an overview of cutting-edge developments of process systems engineering for biopharmaceutical and pharmaceutical manufacturing processes is given, including model-based process design, Digital Twins, computer-aided process understanding, process development and optimization, and monitoring and control of bioprocesses. The biopharmaceutical processes addressed focus on the manufacturing of biopharmaceuticals, mainly by Chinese hamster ovary (CHO) cells, as well as adeno-associated virus production and generation of cell spheroids for cell therapies.
clonal cell population --- phenotypic diversity --- inoculum train --- uncertainty-based --- cell culture model --- biopharmaceutical manufacturing --- Escherichia coli --- hybrid modeling --- machine learning --- model-assisted DoE --- quality by design --- upstream bioprocessing --- surface plasmon resonance (SPR) --- bioprocess --- monitoring --- biosensor --- quality by design (QbD) --- process analytical technology (PAT) --- biotherapeutics production --- vaccines production --- CHO DP-12 --- computational fluid dynamics --- bioreactor characterization --- hydrodynamic gradients --- process development --- critical shear stress --- Kolmogorov length scale --- operational space --- sensors --- cell culture --- spectroscopy --- PAT --- smart biomanufacturing --- soft-sensor --- Adeno-associated virus --- transfection --- PEI --- continuous --- gene therapy --- microcarriers --- bioreactor --- transient expression --- spheroid strength --- β-cells --- diabetes --- shear stress-guided production --- hydrodynamic stress --- Gaussian processes --- Bayes optimization --- Pareto optimization --- multi-objective --- seed train --- Chinese hamster ovary cells --- cryopreservation --- monoclonal antibodies --- N−1 perfusion --- process intensification --- upstream processing --- n/a
Choose an application
In 2015, the first pharmaceutical cocrystal was approved by the FDA. Since then, the number of cocrystals on the market and in the development pipeline has been slowly but steadily growing. It is now well established that cocrystals are a versatile new approach to oral drug formulation. This Reprint Book is a collection of articles that show the utility of pharmaceutical cocrystals and various aspects of cocrystal research: • Cocrystals as a strategy to modify the physicochemical properties of a drug such as dissolution behaviour, tabletability, and melting point; • Development of new coformers; • Screening studies for multiple cocrystal forms; • Cocrystals in nano-sized drug delivery.
Research & information: general --- nitazoxanide --- cocrystals --- multicomponent crystals --- dissolution behavior --- supersaturated formulations --- crystallization inhibitors --- drug-polymer interactions --- nano co-crystals --- crystal engineering --- polydispersity index --- zeta potential --- particle size --- zidovudine --- lamivudine --- HIV/AIDS --- sonochemistry --- imidazole N-oxides --- barbituric acid --- thiobarbituric acid --- pharmaceutical cocrystals --- mechanochemistry --- solid state NMR --- X-ray Diffraction --- design of experiments --- Quality by Design --- cocrystal --- compaction --- nanoindentation --- slip plane --- tabletability --- surface topology --- interparticulate bonding area --- interparticulate bonding strength --- nefiracetam --- solid state --- solubility --- dissolution rate --- stability --- formulation --- diclofenac sodium --- L-proline --- salt cocrystal --- multicomponent crystal --- monohydrate --- tetrahydrate --- dissolution --- itraconazole --- terephthalic acid --- crystal structure --- solid-state --- thermal analysis --- wettability --- n/a
Choose an application
undefined
Research & information: general --- vaccine --- adjuvants --- Sporothrix schenckii --- toluene --- virulence --- enolase --- Montanide PetGel A --- Amphotericin B --- cutaneous leishmaniasis --- hydrogel --- wound dressing --- controlled release --- thermoreversible gel --- poloxamer 407 --- candidiasis --- amphotericin B --- skin and vaginal mucosa --- butenafine --- SNEDDS --- solid SNEDDS --- spray drying --- leishmaniasis --- design of experiments --- orodispersible films --- fast-dissolving films --- micelles --- fungal infections --- aspergillosis --- oral delivery --- chitosan --- shiitake --- Lentinula edodes --- AHCC® --- Molecular Envelope Technology --- praziquantel --- calcium carbonate --- schistosomiasis --- bioavailability --- solubility --- cytotoxicity --- fluconazole --- orthopedic infection --- Poly(d,l-lactide-co-glycolide) beads --- sustained release --- Leishmania infantum --- meglumine antimoniate --- Sepigel 305® --- topical treatment --- polymer micelles --- drug delivery --- liposomes --- transferosomes --- nanoparticles --- emulsions --- azoles --- combined therapy --- quality by design --- malaria --- trypanosomiasis
Choose an application
In 2015, the first pharmaceutical cocrystal was approved by the FDA. Since then, the number of cocrystals on the market and in the development pipeline has been slowly but steadily growing. It is now well established that cocrystals are a versatile new approach to oral drug formulation. This Reprint Book is a collection of articles that show the utility of pharmaceutical cocrystals and various aspects of cocrystal research: • Cocrystals as a strategy to modify the physicochemical properties of a drug such as dissolution behaviour, tabletability, and melting point; • Development of new coformers; • Screening studies for multiple cocrystal forms; • Cocrystals in nano-sized drug delivery.
nitazoxanide --- cocrystals --- multicomponent crystals --- dissolution behavior --- supersaturated formulations --- crystallization inhibitors --- drug-polymer interactions --- nano co-crystals --- crystal engineering --- polydispersity index --- zeta potential --- particle size --- zidovudine --- lamivudine --- HIV/AIDS --- sonochemistry --- imidazole N-oxides --- barbituric acid --- thiobarbituric acid --- pharmaceutical cocrystals --- mechanochemistry --- solid state NMR --- X-ray Diffraction --- design of experiments --- Quality by Design --- cocrystal --- compaction --- nanoindentation --- slip plane --- tabletability --- surface topology --- interparticulate bonding area --- interparticulate bonding strength --- nefiracetam --- solid state --- solubility --- dissolution rate --- stability --- formulation --- diclofenac sodium --- L-proline --- salt cocrystal --- multicomponent crystal --- monohydrate --- tetrahydrate --- dissolution --- itraconazole --- terephthalic acid --- crystal structure --- solid-state --- thermal analysis --- wettability --- n/a
Choose an application
undefined
vaccine --- adjuvants --- Sporothrix schenckii --- toluene --- virulence --- enolase --- Montanide PetGel A --- Amphotericin B --- cutaneous leishmaniasis --- hydrogel --- wound dressing --- controlled release --- thermoreversible gel --- poloxamer 407 --- candidiasis --- amphotericin B --- skin and vaginal mucosa --- butenafine --- SNEDDS --- solid SNEDDS --- spray drying --- leishmaniasis --- design of experiments --- orodispersible films --- fast-dissolving films --- micelles --- fungal infections --- aspergillosis --- oral delivery --- chitosan --- shiitake --- Lentinula edodes --- AHCC® --- Molecular Envelope Technology --- praziquantel --- calcium carbonate --- schistosomiasis --- bioavailability --- solubility --- cytotoxicity --- fluconazole --- orthopedic infection --- Poly(d,l-lactide-co-glycolide) beads --- sustained release --- Leishmania infantum --- meglumine antimoniate --- Sepigel 305® --- topical treatment --- polymer micelles --- drug delivery --- liposomes --- transferosomes --- nanoparticles --- emulsions --- azoles --- combined therapy --- quality by design --- malaria --- trypanosomiasis
Choose an application
Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems.
Medicine. --- plasma half-life extension --- albumin conjugation --- in vivo glucose-lowering activity --- glucagon-like peptide-1 --- quality by design --- rapid equilibrium dialysis --- muco-adhesion --- brain PAMPA --- RPMI 2650 nasal epithelial cell --- human serum albumin --- dimerization --- doxorubicin --- enhanced permeability and retention effect --- antitumor --- Arthrobacter globiformis --- gout --- half-life extension --- inverse electron demand Diels-Alder reaction --- site-specific albumin conjugation --- thermostability --- urate oxidase --- albumin --- anti-thrombotic --- CD39 --- coating of medical devices --- stent coating --- therapeutic fusion protein --- conjugates --- vanadium --- cancer --- prodrug --- hydrogels --- EPR/ESR spectroscopy --- release behavior --- disulfide --- glioma --- conjugate --- albumin binding moieties --- peptides --- Evans blue --- 4-(p-iodophenyl)butyric acid --- integrin αvβ6 --- integrin αvβ6 binding peptide --- improved pharmacokinetics --- PET imaging
Choose an application
undefined
Research & information: general --- vaccine --- adjuvants --- Sporothrix schenckii --- toluene --- virulence --- enolase --- Montanide PetGel A --- Amphotericin B --- cutaneous leishmaniasis --- hydrogel --- wound dressing --- controlled release --- thermoreversible gel --- poloxamer 407 --- candidiasis --- amphotericin B --- skin and vaginal mucosa --- butenafine --- SNEDDS --- solid SNEDDS --- spray drying --- leishmaniasis --- design of experiments --- orodispersible films --- fast-dissolving films --- micelles --- fungal infections --- aspergillosis --- oral delivery --- chitosan --- shiitake --- Lentinula edodes --- AHCC® --- Molecular Envelope Technology --- praziquantel --- calcium carbonate --- schistosomiasis --- bioavailability --- solubility --- cytotoxicity --- fluconazole --- orthopedic infection --- Poly(d,l-lactide-co-glycolide) beads --- sustained release --- Leishmania infantum --- meglumine antimoniate --- Sepigel 305® --- topical treatment --- polymer micelles --- drug delivery --- liposomes --- transferosomes --- nanoparticles --- emulsions --- azoles --- combined therapy --- quality by design --- malaria --- trypanosomiasis --- vaccine --- adjuvants --- Sporothrix schenckii --- toluene --- virulence --- enolase --- Montanide PetGel A --- Amphotericin B --- cutaneous leishmaniasis --- hydrogel --- wound dressing --- controlled release --- thermoreversible gel --- poloxamer 407 --- candidiasis --- amphotericin B --- skin and vaginal mucosa --- butenafine --- SNEDDS --- solid SNEDDS --- spray drying --- leishmaniasis --- design of experiments --- orodispersible films --- fast-dissolving films --- micelles --- fungal infections --- aspergillosis --- oral delivery --- chitosan --- shiitake --- Lentinula edodes --- AHCC® --- Molecular Envelope Technology --- praziquantel --- calcium carbonate --- schistosomiasis --- bioavailability --- solubility --- cytotoxicity --- fluconazole --- orthopedic infection --- Poly(d,l-lactide-co-glycolide) beads --- sustained release --- Leishmania infantum --- meglumine antimoniate --- Sepigel 305® --- topical treatment --- polymer micelles --- drug delivery --- liposomes --- transferosomes --- nanoparticles --- emulsions --- azoles --- combined therapy --- quality by design --- malaria --- trypanosomiasis
Choose an application
Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems.
Medicine. --- plasma half-life extension --- albumin conjugation --- in vivo glucose-lowering activity --- glucagon-like peptide-1 --- quality by design --- rapid equilibrium dialysis --- muco-adhesion --- brain PAMPA --- RPMI 2650 nasal epithelial cell --- human serum albumin --- dimerization --- doxorubicin --- enhanced permeability and retention effect --- antitumor --- Arthrobacter globiformis --- gout --- half-life extension --- inverse electron demand Diels-Alder reaction --- site-specific albumin conjugation --- thermostability --- urate oxidase --- albumin --- anti-thrombotic --- CD39 --- coating of medical devices --- stent coating --- therapeutic fusion protein --- conjugates --- vanadium --- cancer --- prodrug --- hydrogels --- EPR/ESR spectroscopy --- release behavior --- disulfide --- glioma --- conjugate --- albumin binding moieties --- peptides --- Evans blue --- 4-(p-iodophenyl)butyric acid --- integrin αvβ6 --- integrin αvβ6 binding peptide --- improved pharmacokinetics --- PET imaging --- plasma half-life extension --- albumin conjugation --- in vivo glucose-lowering activity --- glucagon-like peptide-1 --- quality by design --- rapid equilibrium dialysis --- muco-adhesion --- brain PAMPA --- RPMI 2650 nasal epithelial cell --- human serum albumin --- dimerization --- doxorubicin --- enhanced permeability and retention effect --- antitumor --- Arthrobacter globiformis --- gout --- half-life extension --- inverse electron demand Diels-Alder reaction --- site-specific albumin conjugation --- thermostability --- urate oxidase --- albumin --- anti-thrombotic --- CD39 --- coating of medical devices --- stent coating --- therapeutic fusion protein --- conjugates --- vanadium --- cancer --- prodrug --- hydrogels --- EPR/ESR spectroscopy --- release behavior --- disulfide --- glioma --- conjugate --- albumin binding moieties --- peptides --- Evans blue --- 4-(p-iodophenyl)butyric acid --- integrin αvβ6 --- integrin αvβ6 binding peptide --- improved pharmacokinetics --- PET imaging
Listing 1 - 10 of 15 | << page >> |
Sort by
|